![](https://monteverdelaw.com/wp-content/uploads/case-logo/sunesis-pharmaceuticals-inc.png)
Sunesis Pharmaceuticals, Inc. (SNSS) relating to its proposed merger with Viracta Therapeutics, Inc. (“Viracta”). Under the terms of the agreement, Sunesis shareholders will only 14% of the combined company, with Viracta owning the other 86%.
Sunesis Pharmaceuticals, Inc. (SNSS) relating to its proposed merger with Viracta Therapeutics, Inc. (“Viracta”). Under the terms of the agreement, Sunesis shareholders will only 14% of the combined company, with Viracta owning the other 86%.